Abstract
Update of recent studies in chronic myeloid leukemia
Highlights
Current trends in leukemia, lymphoma, myeloma and ITP: updates and highlights from ASH 2008 Delong Liu Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1756-8722-2-S1-info.pdf
This study demonstrated that patients receiving imatinib 800 mg achieved a major molecular remission (MMR) and/ or complete cytogenetic remission (CCyR) faster than patients receiving imatinib 400 mg
When time to response was measured on the German chronic myeloid leukemia (CML) Study IV, achievement of MMR by 18 months was a strong predictor of event free survival [5]
Summary
Current trends in leukemia, lymphoma, myeloma and ITP: updates and highlights from ASH 2008 Delong Liu Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1756-8722-2-S1-info.pdf . The use of tyrosine kinase inhibitors (TKIs) has dramatically improved outcomes for patients with chronic myeloid leukemia (CML). The IRIS study is the definitive phase III trial of imatinib mesylate as frontline therapy for CML.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
